Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., November 16, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today

Event · Earnings
Original reporting
Published Nov 16, 2026, 12:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GALT
Bullish
high confidence
Mentioned
$GALT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GALTBullishMed
01

Why it matters

The combination of financial improvement and clinical progress provides a fresh catalyst for GALT.

02

Market read

First‑report of earnings and trial data creates a material news event for GALT and its sector.

03

What to watch

Remaining enrollment risk in the Phase 3 trial and reliance on a single lead candidate.

Relevance 7/10Novelty 8/10Timing: immediate release today

Background

The filing is a standard quarterly update but includes first‑time disclosure of Phase 3 protocol and new trial efficacy metrics.

Company-level read

Ticker impact

$GALTBullishHigh confidence
Context

Galectin Therapeutics filed an 8‑K reporting Q3 2026 results, disclosed Phase 3 protocol submission and positive belapectin trial data, and converted $105.8 M of debt to equity.

Expected impact

potential upside as investors price in efficacy signals and debt reduction

Evidence & confidence

Phase 3 protocol filing and statistically significant reduction in portal‑hypertension risk are material for a biotech; debt conversion improves cash runway, both likely to support price gains.

Market effects

strengthens outlook for liver‑disease therapeutics and may boost peer biotech valuations

U.S. biotech sector could see modest gains

adds to global pipeline confidence for galectin‑targeted drugs

Counterpoint

Trial data, while statistically significant, may not translate to regulatory approval; investors could be cautious.

Key entities

  • Galectin Therapeutics

    NASDAQ‑listed biotech developing belapectin for liver disease.

  • Richard E. Uihlein

    Chairman and largest shareholder who converted debt to equity.

Related articles

$GALTMedAI 8/10

Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

Galectin Therapeutics (NASDAQ:GALT) reported Q2 2026 results for the three months ended June 30, 2026 and said it reached agreement with the FDA on Phase 3 belapectin trial elements for MASH cirrhosis and portal hypertension, targeting protocol submission in 3Q 2026. Cash was $13.2M; net loss was $9.2M ($0.14/share). Chairman Uihlein converted about $105.8M debt into 34.4M shares.

$GALTMed

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., August 14, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reporte

$GALTMedAI 8/10

Galectin Therapeutics Inc.: Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Galectin Therapeutics (NASDAQ: GALT) said Chairman Richard E. Uihlein converted all outstanding principal and accrued interest under five line-of-credit facilities into common stock effective July 31, 2026. The deal eliminated about $105.8 million of debt (about $91.0 million principal, $14.8 million interest) and issued 34,376,167 shares at a blended $3.07 conversion price. A sixth $10 million facility remains undrawn.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.